Lifesci Capital Comments on JANX Q2 Earnings

Key Points

• Lifesci Capital forecast Janux Therapeutics will post a Q2 2026 loss of $0.50 per share, with full-year 2026 EPS estimated at ($2.29).
• The company reported a smaller-than-expected Q2 loss of $0.39 per share, beating the consensus estimate of a $0.52 loss, but revenue of $3.73 million missed expectations.
• Analyst sentiment remains mixed but generally constructive: Janux has a Moderate Buy consensus rating, though several firms recently cut price targets while keeping positive ratings.

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Equities research analysts at Lifesci Capital issued their Q2 2026 earnings per share estimates for Janux Therapeutics in a research note issued to investors on Friday, May 8th. Lifesci Capital analyst O. Mccammon forecasts that the company will earn ($0.50) per share for the quarter. The consensus estimate for Janux Therapeutics' current full-year earnings is ($2.33) per share. Lifesci Capital also issued estimates for Janux Therapeutics' Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($2.29) EPS.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million.

Several other analysts have also commented on the company. Weiss Ratings raised Janux Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, April 22nd. Clear Str lowered Janux Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, January 20th. Truist Financial raised Janux Therapeutics to a "strong-buy" rating in a report on Monday, May 4th. Wedbush dropped their target price on Janux Therapeutics from $45.00 to $36.00 and set an "outperform" rating on the stock in a report on Friday. Finally, Guggenheim dropped their target price on Janux Therapeutics from $68.00 to $58.00 and set a "buy" rating on the stock in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Janux Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $47.83.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $14.18 on Monday. The stock's 50-day simple moving average is $14.35 and its 200-day simple moving average is $17.45. The firm has a market capitalization of $864.70 million, a PE ratio of -7.71 and a beta of 2.58. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34.

Hedge Funds Weigh In On Janux Therapeutics

Hedge funds have recently bought and sold shares of the business. Nano Cap New Millennium Growth Fund L P purchased a new position in Janux Therapeutics during the fourth quarter worth approximately $34,000. Osaic Holdings Inc. boosted its position in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company's stock worth $80,000 after purchasing an additional 3,037 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Janux Therapeutics in the fourth quarter valued at approximately $51,000. Tower Research Capital LLC TRC lifted its position in shares of Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company's stock valued at $91,000 after acquiring an additional 2,502 shares in the last quarter. Finally, Winthrop Capital Management LLC purchased a new position in shares of Janux Therapeutics in the third quarter valued at approximately $106,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics News Summary

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: The company reported a smaller-than-expected quarterly loss of $0.39 per share, beating estimates of a $0.52 loss, which may help support investor sentiment. Press Release
• Neutral Sentiment: Revenue came in at $3.73 million, below analyst expectations of $4.36 million, offsetting some of the earnings beat and limiting the immediate upside reaction.
• Neutral Sentiment: Guggenheim lowered its price target to $58 from $68 but maintained a Buy rating, signaling continued long-term confidence despite trimming expectations.
• Neutral Sentiment: Wedbush cut its target to $36 from $45 and kept an Outperform rating, indicating analysts still see meaningful upside but are becoming more cautious.
• Negative Sentiment: Piper Sandler reduced its target to $26 from $30, though it maintained an Overweight rating, adding to the theme of lower near-term valuation expectations.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.